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Stat5a serine phosphorylation regulates Stat5a nuclear ac-
tivity in a non-canonical fashion, contributing to its role in 
mammary oncogenesis. As shown in a tissue microarray 
(TMA), human breast cancer tissues express both pS726- 
and pS780-Stat5a. Nuclear Allred score for pS726-Stat5a 
increases two-fold with increasing tumor grade, with no 
difference in staining associated with estrogen or proges-
terone receptor (ER, PR) status, nor other clinical charac-
teristics. Likewise, patient derived xenograft (PDX) tumors 
of various molecular subtypes express pS726- and pS780-
Stat5a. Phosphorylation of S726-Stat5a is PRL-responsive 
in vitro. Pharmacologic inhibition of ERK1/2 prevents this 
phosphorylation, uncovering a novel pathway in which 
ERK1/2 mediates Stat5a activity in response to PRL in 
breast cancer. To examine the functional significance of 
Stat5a serine phosphorylation in vitro, we have performed 
Stat5a knockdown (KD) in the breast cancer cell line MCF7. 
Following Stat5a KD, cells were rescued with phospho-site 
specific Stat5a mutant constructs. Characteristics of breast 
cancer examined in these mutation-carrying cells, including 
anchorage-independent growth and proliferation, show dis-
tinct phenotypes compared to controls. PRL-induced ex-
pression of the CISH gene is significantly decreased up to 
65% in the mutation-carrying cells compared to wild type 
Stat5a. Mechanistic studies will examine the ability of 
these Stat5a mutants to undergo nuclear translocation and 
interact with other transcription factors. Collectively, these 
studies have the potential to provide novel insights into the 
role of the non-canonical pathway of Stat5a activation in 
breast cancer pathogenesis.
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Objective: There is paucity of literature on the impact of 
age on outcomes hyperosmolar hyperglycemic state (HHS) 
among adult patients with diabetes. The aim of the study 
was to evaluate the effect of age on the outcome of patients 
admitted for the management of HHS. Methodology: 
The National Inpatient Sample (NIS) was queried for 
all patients who were admitted with a diagnosis of HHS 
during the years 2005-2014. The primary outcomes of the 
study were all-cause mortality, acute myocardial infarc-
tion (MI), and acute stroke. The secondary outcomes were 
acute kidney injury (AKI), rhabdomyolysis, acute respira-
tory failure (ARF), need for mechanical ventilation (MV) 
length of stay (LOS), and total cost of stay. Results: Overall, 
188,725 patients were admitted for HHS. Mean age was 
55.9, standard error of the mean (SEM): 0.1. Majority were 
of middle age. Females were (43.9%), Caucasians were 
37.4% while African Americans were 35.2%. Total mortality 
was 1.1%, MI was 1.3% and stroke was 1.1%. Most common 
secondary outcome was AKI seen in 31.3% followed by ARF 
seen in 2.9% of total. The mean cost was 7887  $ (SEM: 
84.6) and mean LOS was 4.1 days (SEM: 0.03). Young age 
was defined as age ≤ 35 years, middle age was > 35 and ≤ 
65 years, old age was > 65 years. Mortality was 0.3 %, 0.6%, 
2.5% in young, middle and older aged groups respectively. 
Similarly, higher age correlated with increased risk for 
MI, stroke and all secondary outcomes. On multivariable 
analysis, age was an independent predictor for all adverse 
outcomes. Compared to young patients, middle and older 
age groups had higher odds for mortality with adjusted 
odds ratio (aOR) 2.23 [95%CI:1.10-4.52], p=0.03 and aOR 
7.35 [95%CI: 3.27-16.53], p<0.001 respectively, higher 
risk for stroke with aOR 9.32 [95%CI: 2.92-29.7], p<0.001 
and aOR 17.46 [95%CI:5.23-58.3], p<0.001 and higher 
risk for MI aOR 5.18 [95%CI:2.15-12.51], p<0.00 and aOR 
5.80 [95%CI:2.27-14.80], p<0.00 for middle and older age 
groups respectively. In addition, compared to the younge 
age group, the risk for rhabdomyolysis, AKI, ARF, MV, total 
cost and LOS was significantly higher among middle and 
older age groups respectively. Conclusion: Age is an im-
portant determinant for adverse outcomes among patients 
with hyperosmolar hyperglycemic sate.
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Hormone receptor-positive (HR+, estrogen and/or proges-
terone receptor-positive) and HER2-negative breast cancer 
(BC) subtype is a biologically heterogeneous entity that 
comprises 70% of BCs. This subtype includes both luminal 
(Lum) A- and B-like subtypes, which have differences in 
prognosis and sensitivity to endocrine therapies. The de-
velopment of biomarkers guiding treatment decisions in 
these settings is required. Tumor suppressor PDCD4 (pro-
grammed cell death 4), which can be found both in the 
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tumor growth and metastasis, and its loss is associated 
with poor prognosis in solid tumors. To explore the clinical 
relevance of PDCD4 in BC, we analyzed its expression by 
immunohistochemistry in a cohort of 619 patients with pri-
mary invasive BC. We found that 34.7% of patients showed 
NPDCD4 and 21.3% showed CPDCD4. NPDCD4 positivity, 
but not CPDCD4, was associated with lower clinical stage 
(P = 0.0003), with presence of more differentiated tumors 
(P = 6.4x10-6), and with estrogen and progesterone receptor 
(PR) expression (P  =  9.2x10-9 and P  =  2.8x10-9, respec-
tively). Kaplan-Meier analysis revealed that NPDCD4 ex-
pression was associated with a longer overall survival (OS) 
and disease-free survival (DFS) in LumA-like (P  =  0.008 
and P = 0.028, respectively) and LumB-like (P = 0.004 and 
P  =  0.012, respectively) subtypes. Interestingly, patients 
with LumB-like tumors displaying NPDCD4 presented 
estimated OS and DFS rates similar to the ones observed in 
patients with LumA-like tumors also expressing NPDCD4, 
indicating that its presence improves the clinical outcome 
of LumB-like patients. Multivariate Cox regression anal-
ysis identified NPDCD4 as an independent predictor of 
good clinical outcome in both LumA-like (HR: 0.45, 95% CI 
0.22-0.96, P = 0.038) and LumB-like (HR: 0.28, 95% CI 0.10-
0.80, P = 0.018) subtypes. We validated our results by in 
silico analysis using expression data from the METABRIC 
cohort. Bioinformatics analysis of BC cells from the Cancer 
Cell Line Encyclopedia revealed a positive correlation be-
tween PDCD4 and PR expression (P = 0.015). Since LumB-
like tumors present a higher risk of resistance to endocrine 
therapy and both PR and PDCD4 levels in this subtype are 
lower than in the LumA-like one, we postulated that the 
presence of PR may modulate PDCD4 expression. Silencing 
of PR expression in HR+ cells decreased PDCD4 protein 
levels while reconstitution of PR in a PR-null cell line 
increased them, confirming PR requirement for PDCD4 
modulation. In line with PDCD4 physiological function, its 
knockdown increased cell migration capability of HR+ BC 
cells, whereas its restoration led to a decrease in cell mi-
gration of HR-negative BC models. Our findings identified 
NPDCD4 positivity as a novel biomarker of clinical out-
come in LumA- and B-like subtypes and revealed PDCD4 
reconstitution as a novel therapeutic strategy in BC.
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Background:
Insulinoma is the most common type of functioning pancre-
atic neuroendocrine tumor (NET). Polyhormonal secretions 
from the NET, giving rise to distinct clinical symptoms such 
as carcinoid symptoms are rare. Clinical Case: We report a 
68-year-old woman who presented with four months history 
of recurrent diaphoresis, palpitations, tremors and chest 
tightness. These were associated with episodic paroxysms 
of flushing and diarrhoea. The physical examination was 
unremarkable. She was a well-nourished woman with BMI 
of 28  kg/m2. Initial laboratory tests ruled out any renal, 
liver abnormalities with normal cortisol and thyroid func-
tion test. Further evaluation confirms insulin mediated 
hypoglycaemia with low random blood sugar 2.5  mmol/l 
(4.4-7.8) and failure to suppress C-peptide, 1092 pmol/L 
(298-2350) and insulin levels, 12.7 mU/L (3-25). Urine 
5-HIAA was markedly elevated 2430.37  µmol/day (3.66-
42.89) with borderline elevation of serum chromogranin 
A  level 122  ng/mL (27-94). IGF-1 was also raised at 416 
ug/L (91-282). Two months later she presented with new 
onset of delirium, incoherence, agitation and restlessness 
independent of her hypoglycaemic events. These symptoms 
deteriorated and fluctuates throughout the day with pe-
riod of normalcy in between. This has led to requirement 
of a full time caregiver for her. Cranial CT excluded any 
brain pathology. We are faced with a diagnostic challenge 
to localize the primary lesion as radiological imaging so far 
were normal. GALLIUM-68 PET CT showed physiological 
uptake in the uncinate process of the pancreas (SUVmax 
14.4). Endoscopic ultrasound of the pancreas was normal. 
An intra-arterial calcium stimulation test with hepatic 
venous sampling (ASVS) confirms a lesion at the head of 
pancreas with two times increment of insulin from baseline 
at the gastroduodenal artery distribution. Despite elimina-
tion of hypoglycaemic events with Diazoxide 100mg twice 
daily, her neuropsychiatric symptoms persisted. We postu-
late that this might be from excessive peripheral produc-
tion of serotonin by the pancreatic carcinoid tumour or a 
niacin deficiency state because of metabolic diversion of its 
precursor, tryptophan. Conclusion:
This case highlights the occurrence of debilitating neu-
ropsychiatry manifestations in a likely neuroendocrine 
tumour arising from the head of pancreas secreting insulin, 
serotonin and IGF-1.
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Background- The commonest cause of euvolemic 
hyponatremia (EvHNa) is the syndrome of inappropriate 
antidiuretic hormone secretion (SIADH). The diagnosis of 
SIADH requires the exclusion of secondary adrenal insuf-
ficiency (AI) and untreated hypothyroidism. Studies have 
suggested about 4% of unselected patients presenting to 
the emergency room with EvHNa have undiagnosed SAI.1 
Among patients admitted to specialized endocrine units 
this prevalence maybe as high as 20%.2 Objective- To study 
the prevalence of undiagnosed AI among inpatients with 
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